ArticleFrontiers in oncology2026
Clinicopathologic correlates of Ewing (FET::ETS-rearranged) sarcoma and non-Ewing undifferentiated small round cell sarcomas across skeletal and extraskeletal sites.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: FET::ETS-rearranged Ewing sarcoma (ES) and non-Ewing undifferentiated small round-cell sarcomas (SRCSs) comprise a morphologically overlapping yet molecularly diverse group of aggressive sarcomas. They differ in genotype, anatomic distribution, age profile, and clinical behavior. Clarifying genotype-anatomic correlations-particularly distinctions between ES and non-Ewing SRCSs, as well as between skeletal and extraskeletal presentations within the Ewing group-is essential for accurate diagnosis and treatment planning, especially in morphologically ambiguous cases. Methods: Ninety undifferentiated SRCSs of bone and soft tissue diagnosed between 2016 and 2025 at a tertiary cancer center were retrospectively reviewed. Clinical, histopathologic, and molecular data were analyzed using targeted RNA next-generation sequencing (Archer FusionPlex Sarcoma Panel) and break-apart fluorescence Results: Among 90 cases (47 males, 43 females; median age 18.5 years), 76 (84%) harbored FET::ETS fusions and/or Conclusion: ES and non-Ewing SRCSs exhibit morphologic overlap but differ in genotype, anatomic distribution, and age pattern. Within the Ewing group, skeletal versus extraskeletal presentation did not influence outcome, despite clear age differences. Integrating molecular diagnostics with site-specific and histopathologic assessment enhances diagnostic accuracy and guides management of these biologically diverse tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.